Application of IER3 as biomarker in early prediction of sepsis

Abstract

The invention relates to the technical field of biology, in particular to application of an early response gene 3 (IER3) as a biomarker in a reagent or a kit for early prediction of sepsis. The IER3 is adopted as a biomarker, and crowd experiments prove that the IER3 level of plasma of a patient suffering from severe trauma sepsis is remarkably higher than that of a patient without sepsis. By detecting the plasma IER3 level, early prediction is conducted on the sepsis occurrence risk of a severely wounded patient so as to give individualized interventional therapy, the occurrence rate of post-traumatic sepsis can be reduced, and the important clinical application value can be achieved for improving prognosis of the severely wounded patient.

Description

technical field

[0001] The invention belongs to the field of biotechnology and relates to the application of an early response gene 3 as a biomarker in the early prediction of sepsis. Background technique

[0002] Trauma is a global public health problem, and the number of deaths due to trauma is as high as 5 million every year, accounting for 10% of the total global disease burden. With the advancement of pre-hospital first aid technology and the improvement of the monitoring and treatment system, the direct mortality rate caused by injuries in the early stage of trauma has been significantly reduced, but complications such as sepsis and multiple organ dysfunction in the post-trauma period are still a serious threat patient survival.

[0003] Sepsis is a life-threatening organ dysfunction caused by the dysregulation of the host's immune response to infection. It is a common serious complication and the main cause of death in critically ill patients with infection, burn / tra...

Images